PSILOCYBIN IN PSYCHIATRIC PRACTICE AND PSYCHEDELIC-ASSISTED THERAPY FOR TREATMENT-RESISTANT DEPRESSION
Abstract
This manuscript comprehensively reviews psilocybin-assisted therapy for major depressive disorder and treatment-resistant depression. It aims to synthesize current understanding regarding its mechanisms, efficacy, safety, costs, and accessibility, comparing it with conventional antidepressant and ketamine treatments. The methodology involved a narrative synthesis of academic literature, drawing from systematic reviews, meta-analyses, and clinical trials identified through targeted database searches.
Key findings indicate that psilocybin therapy demonstrates rapid, robust, and sustained antidepressant effects, with high response and remission rates, often after one or two sessions. Its safety profile is generally favorable, with transient and mild adverse events. Mechanistically, psilocybin primarily acts on serotonin 5-HT2A receptors, modulating brain networks and enhancing neuroplasticity. However, significant challenges exist in terms of high costs, limited accessibility due to the intensive therapeutic model, and regulatory hurdles.
In conclusion, psilocybin-assisted therapy offers a promising alternative for depression, particularly where standard treatments fail, by providing rapid and durable symptom reduction through unique neurobiological pathways. Future research should focus on optimizing treatment protocols, exploring long-term outcomes, identifying predictors of response, and addressing systemic barriers to accessibility and cost-effectiveness to facilitate its integration into broader mental healthcare.
References
Aleksandrova, L. R., & Phillips, A. G. (2021). Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics [Review of Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics]. Trends in Pharmacological Sciences, 42(11), 929. Elsevier BV. https://doi.org/10.1016/j.tips.2021.08.003
Atiq, M. A., Baker, M., Voort, J. L. V., Vargas, M. V., & Choi, D. (2024). Disentangling the acute subjective effects of classic psychedelics from their enduring therapeutic properties [Review of Disentangling the acute subjective effects of classic psychedelics from their enduring therapeutic properties]. Psychopharmacology. Springer Science+Business Media. https://doi.org/10.1007/s00213-024-06599-5
Avanceña, A. L. V., Vuong, L. N., Kahn, J. G., & Marseille, E. (2025). Psilocybin-assisted therapy for treatment-resistant depression in the US: a model-based cost-effectiveness analysis. Translational Psychiatry, 15(1), 330. https://doi.org/10.1038/s41398-025-03556-4
Bahji, A., Lunsky, I., Gutiérrez, G., & Vázquez, G. (2023). Efficacy and Safety of Four Psychedelic-Assisted Therapies for Adults with Symptoms of Depression, Anxiety, and Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis [Review of Efficacy and Safety of Four Psychedelic-Assisted Therapies for Adults with Symptoms of Depression, Anxiety, and Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis]. Journal of Psychoactive Drugs, 1. Taylor & Francis. https://doi.org/10.1080/02791072.2023.2278586
Beau, K., Michelle, P., Rajeev, R., C., R., Rhianna, Ben, S., & Keytin, P. (2024). Considering Alternatives to Psychedelic Drug Prohibition. In RAND Corporation eBooks. https://doi.org/10.7249/rra2825-1
Belouin, S. J., Averill, L. A., Henningfield, J. E., Xenakis, S. N., Donato, I., Grob, C. S., Berger, A. M., Magar, V., Danforth, A., & Anderson, B. (2022). Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines [Review of Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines]. Neuropharmacology, 219, 109214. Elsevier BV. https://doi.org/10.1016/j.neuropharm.2022.109214
Brennan, B., & Belser, A. B. (2022). Models of Psychedelic-Assisted Psychotherapy: A Contemporary Assessment and an Introduction to EMBARK, a Transdiagnostic, Trans-Drug Model. Frontiers in Psychology, 13. https://doi.org/10.3389/fpsyg.2022.866018
Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of Psilocybin versus Escitalopram for Depression. New England Journal of Medicine, 384(15), 1402. https://doi.org/10.1056/NEJMoa2032994
Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., Rickard, J. A., Forbes, B., Feilding, A., Taylor, D., Curran, H. V., & Nutt, D. J. (2018). Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology, 235(2), 399. https://doi.org/10.1007/s00213-017-4771-x
Ching, T. H. W., Amoroso, L., Bohner, C., D’Amico, E. J., Eilbott, J., Entezar, T., Fitzpatrick, M., Fram, G., Grazioplene, R., Hokanson, J., Jankovsky, A., Kichuk, S. A., Martins, B., Patel, P., Schaer, H., Shnayder, S., Witherow, C., Pittenger, C., & Kelmendi, B. (2024). Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings. Frontiers in Psychiatry, 14. https://doi.org/10.3389/fpsyt.2023.1278823
Costagliola, C., Parmeggiani, F., Semeraro, F., & Sebastiani, A. (2008). Selective Serotonin Reuptake Inhibitors: A Review of its Effects on Intraocular Pressure [Review of Selective Serotonin Reuptake Inhibitors: A Review of its Effects on Intraocular Pressure]. Current Neuropharmacology, 6(4), 293. Bentham Science Publishers. https://doi.org/10.2174/157015908787386104
Crane, M. A., DiStefano, M. J., & Moore, T. J. (2023). False or Misleading Claims in Online Direct-to-Consumer Ketamine Advertising in Maryland. JAMA Network Open, 6(11). https://doi.org/10.1001/jamanetworkopen.2023.42210
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 78(5), 481. https://doi.org/10.1001/jamapsychiatry.2020.3285
Daws, R. E., Timmermann, C., Giribaldi, B., Sexton, J. D., Wall, M. B., Erritzoe, D., Roseman, L., Nutt, D., & Carhart-Harris, R. (2022). Increased global integration in the brain after psilocybin therapy for depression. Nature Medicine, 28(4), 844. https://doi.org/10.1038/s41591-022-01744-z
Dorval, M., Chang, S.-L., Farzin, H., Nguyen, O., Stephan, J.-F., Tapp, D., Deschamps, P., Joly, Y., Moureaux, F., Foxman, R., Masse-Grenier, M., & Fallu, J. (2025). Roadmap for Equitable Access and Responsible Use of Psilocybin-Assisted Psychotherapy in Palliative Care. Palliative Medicine Reports, 6(1), 153. https://doi.org/10.1089/pmr.2024.0108
Edinoff, A. N., Akuly, H. A., Hanna, T. A., Ochoa, C., Patti, S. J., Ghaffar, Y. A., Kaye, A. D., Viswanath, O., Urits, I., Boyer, A. G., Cornett, E. M., & Kaye, A. M. (2021). Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review [Review of Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review]. Neurology International, 13(3), 387. PAGEPress (Italy). https://doi.org/10.3390/neurolint13030038
Erritzøe, D., Barba, T., Greenway, K. T., Murphy, R., Martell, J., Giribaldi, B., Timmermann, C., Murphy-Beiner, A., Jones, M. B., Nutt, D., Weiss, B., & Carhart‐Harris, R. (2024). Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial. EClinicalMedicine, 76, 102799. https://doi.org/10.1016/j.eclinm.2024.102799
Europe, T. L. R. H. –. (2023). Psychedelic-assisted psychotherapy: hope and dilemma. The Lancet Regional Health - Europe, 32, 100727. https://doi.org/10.1016/j.lanepe.2023.100727
Fang, S., Yang, X., & Zhang, W. (2024). Efficacy and acceptability of psilocybin for primary or secondary depression: A systematic review and meta-analysis of randomized controlled trials [Review of Efficacy and acceptability of psilocybin for primary or secondary depression: A systematic review and meta-analysis of randomized controlled trials]. Frontiers in Psychiatry, 15. Frontiers Media. https://doi.org/10.3389/fpsyt.2024.1359088
Feulner, L., Sermchaiwong, T., Rodland, N., & Galarneau, D. (2023). Efficacy and Safety of Psychedelics in Treating Anxiety Disorders. Ochsner Journal, 23(4), 315. https://doi.org/10.31486/toj.23.0076
Fluyau, D., Kailasam, V. K., & Revadigar, N. (2024). Rapid and prolonged antidepressant and antianxiety effects of psychedelics and 3, 4-methylenedioxy-methamphetamine. A systematic review and meta-analysis [Review of Rapid and prolonged antidepressant and antianxiety effects of psychedelics and 3, 4-methylenedioxy-methamphetamine. A systematic review and meta-analysis]. medRxiv (Cold Spring Harbor Laboratory). Cold Spring Harbor Laboratory. https://doi.org/10.1101/2024.06.17.24308787
Garel, N., Drury, J., Lévesque, J. T., Goyette, N., Lehmann, A., Looper, K., Erritzøe, D., Dames, S., Turecki, G., Rej, S., Richard‐Devantoy, S., & Greenway, K. T. (2023). The Montreal model: an integrative biomedical-psychedelic approach to ketamine for severe treatment-resistant depression. Frontiers in Psychiatry, 14. https://doi.org/10.3389/fpsyt.2023.1268832
Gattuso, J. J., Perkins, D., Ruffell, S., Lawrence, A. J., Hoyer, D., Jacobson, L. H., Timmermann, C., Castle, D., Rossell, S. L., Downey, L. A., Pagni, B. A., Galvão-Coelho, N. L., Nutt, D., & Sarris, J. (2022). Default Mode Network Modulation by Psychedelics: A Systematic Review. International Journal of Neuropsychopharmacology, 26(3), 155. https://doi.org/10.1093/ijnp/pyac074
Goodwin, G. M., Aaronson, S. T., Alvarez, O., Atli, M., Bennett, J. C., Croal, M., DeBattista, C., Dunlop, B. W., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Lennard-Jones, M. R., Licht, R. W., Marwood, L., Mistry, S., Páleníček, T., Redjep, O., Repantis, D., … Malievskaia, E. (2023). Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life. Journal of Affective Disorders, 327, 120. https://doi.org/10.1016/j.jad.2023.01.108
Goodwin, G. M., Croal, M., Feifel, D., Kelly, J. R., Marwood, L., Mistry, S., O’Keane, V., Peck, S. K., Simmons, H., Sisa, C., Stansfield, S. C., Tsai, J., Williams, S., & Malievskaia, E. (2023). Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacology, 48(10), 1492. https://doi.org/10.1038/s41386-023-01648-7
Gukasyan, N., Davis, A. K., Barrett, F. S., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., & Griffiths, R. R. (2022). Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. Journal of Psychopharmacology, 36(2), 151. https://doi.org/10.1177/02698811211073759
Haikazian, S., Chen-Li, D. C. J., Johnson, D. E., Fancy, F., Levinta, A., Husain, M. I., Mansur, R. B., McIntyre, R. S., & Rosenblat, J. D. (2023). Psilocybin-assisted therapy for depression: A systematic review and meta-analysis. Psychiatry Research, 329, 115531. https://doi.org/10.1016/j.psychres.2023.115531
Johnson, M., Richards, W., & Griffiths, R. (2008). Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology, 22(6), 603. https://doi.org/10.1177/0269881108093587
Joshi, K., Liberman, J. N., Parab, P., Darer, J., & Harding, L. (2024). Barriers to Esketamine Nasal Spray Treatment Among Adults With Treatment-Resistant Depression. The Journal of Clinical Psychiatry, 85(2). https://doi.org/10.4088/jcp.23m15102
Kolasa, M., Nikiforuk, A., Korlatowicz, A., Solich, J., Potasiewicz, A., Dziedzicka‐Wasylewska, M., Bugno, R., Hogendorf, A. S., Bojarski, A. J., & Faron‐Górecka, A. (2024). Unraveling psilocybin’s therapeutic potential: behavioral and neuroplasticity insights in Wistar-Kyoto and Wistar male rat models of treatment-resistant depression. Psychopharmacology. https://doi.org/10.1007/s00213-024-06644-3
Li, L., Yu, M., Shi, Z.-M., Huang, X., Ning, Y.-P., Wu, H., Yang, X.-H., & Zheng, W. (2024). Psilocybin for major depressive disorder: a systematic review of randomized controlled studies [Review of Psilocybin for major depressive disorder: a systematic review of randomized controlled studies]. Frontiers in Psychiatry, 15, 1416420. Frontiers Media. https://doi.org/10.3389/fpsyt.2024.1416420
Marseille, E., Bertozzi, S., & Kahn, J. G. (2022). The economics of psychedelic-assisted therapies: A research agenda [Review of The economics of psychedelic-assisted therapies: A research agenda]. Frontiers in Psychiatry, 13, 1025726. Frontiers Media. https://doi.org/10.3389/fpsyt.2022.1025726
Marseille, E., Stauffer, C. S., Agrawal, M., Thambi, P., Roddy, K., Mithoefer, M. C., Bertozzi, S., & Kahn, J. G. (2023). Group psychedelic therapy: empirical estimates of cost-savings and improved access. Frontiers in Psychiatry, 14. https://doi.org/10.3389/fpsyt.2023.1293243
McCrone, P., Fisher, H., Knight, C., Harding, R., Schlag, A. K., Nutt, D., & Neill, J. C. (2023). Cost-effectiveness of psilocybin-assisted therapy for severe depression: exploratory findings from a decision analytic model. Psychological Medicine, 53(16), 7619. https://doi.org/10.1017/s0033291723001411
McGuire, A. L., Cohen, I. G., Sisti, D., Baggott, M. J., Celidwen, Y., Devenot, N., Gracias, S., Grob, C. S., Harvey, I., Kious, B. M., Marks, M., Mithoefer, M. C., Nielson, E. M., Öngür, D., Pallas, A., Peterson, A., Schenberg, E. E., Summergrad, P., Waters, B., … Yaden, D. B. (2024). Developing an Ethics and Policy Framework for Psychedelic Clinical Care: A Consensus Statement. JAMA Network Open, 7(6). https://doi.org/10.1001/jamanetworkopen.2024.14650
Nigam, K., King, F., & Forcén, F. E. (2024). Advancing ketamine in the treatment hierarchy for refractory depression. The British Journal of Psychiatry, 1. https://doi.org/10.1192/bjp.2024.217
Perez, N., Langlest, F., Mallet, L., De Pieri, M., Sentissi, O., Thorens, G., Seragnoli, F., Zullino, D., Kirschner, M., Kaiser, S., Solmi, M., & Sabé, M. (2023). Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies. European Neuropsychopharmacology, 76, 61. https://doi.org/10.1016/j.euroneuro.2023.07.011
Peselow, E. D., Tobia, G., Karamians, R., Pizano, D., & IsHak, W. W. (2014). Prophylactic efficacy of fluoxetine, escitalopram, sertraline, paroxetine, and concomitant psychotherapy in major depressive disorder: Outcome after long-term follow-up. Psychiatry Research, 225(3), 680. https://doi.org/10.1016/j.psychres.2014.11.022
Psiuk, D., Nowak, E. M., Dycha, N., Łopuszańska, U., Kurzepa, J., & Samardakiewicz, M. (2022). Esketamine and Psilocybin—The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review. International Journal of Molecular Sciences, 23(19), 11450. https://doi.org/10.3390/ijms231911450
Rosenblat, J. D., Meshkat, S., Doyle, Z., Kaczmarek, E., Brudner, R. M., Kratiuk, K., Mansur, R. B., Schulz-Quach, C., Sethi, R., Abate, A., Ali, S., Bawks, J., Blainey, M. G., Brietzke, E., Cronin, V., Danilewitz, J., Dhawan, S., Di Fonzo, A., Di Fonzo, M., … McIntyre, R. S. (2024). Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin. Med, 5(3), 190. https://doi.org/10.1016/j.medj.2024.01.005
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165. https://doi.org/10.1177/0269881116675512
Rotz, R. von, Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., & Vollenweider, F. X. (2023). Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine, 56. https://doi.org/10.1016/j.eclinm.2022.101809
Shore, R., Ioudovski, P., Goldie, C., McKeown, S., & Dumont, É. C. (2019). Mapping Psilocybin-Assisted Therapies: A Scoping Review [Review of Mapping Psilocybin-Assisted Therapies: A Scoping Review]. medRxiv (Cold Spring Harbor Laboratory). Cold Spring Harbor Laboratory. https://doi.org/10.1101/2019.12.04.19013896
Szafoni, S., Gręblowski, P., Grabowska, K., & Więckiewicz, G. (2024). Unlocking the healing power of psilocybin: an overview of the role of psilocybin therapy in major depressive disorder, obsessive-compulsive disorder and substance use disorder. Frontiers in Psychiatry, 15. https://doi.org/10.3389/fpsyt.2024.1406888
Villiger, D. (2024). How to Make Psychedelic-Assisted Therapy Safer. Cambridge Quarterly of Healthcare Ethics, 1. https://doi.org/10.1017/s0963180124000604
Voderholzer, U., Barton, B. B., Favreau, M., Zisler, E. M., Rief, W., Wilhelm, M., & Schramm, E. (2024). Enduring effects of psychotherapy, antidepressants and their combination for depression: a systematic review and meta-analysis [Review of Enduring effects of psychotherapy, antidepressants and their combination for depression: a systematic review and meta-analysis]. Frontiers in Psychiatry, 15, 1415905. Frontiers Media. https://doi.org/10.3389/fpsyt.2024.1415905
Williams, M. L., Korevaar, D., Harvey, R., Fitzgerald, P. B., Liknaitzky, P., O’Carroll, S., Puspanathan, P., Ross, M., Strauss, N., & Bennett–Levy, J. (2021). Translating Psychedelic Therapies From Clinical Trials to Community Clinics: Building Bridges and Addressing Potential Challenges Ahead. Frontiers in Psychiatry, 12. https://doi.org/10.3389/fpsyt.2021.737738
Yao, Y., Guo, D., Lu, T.-S., Liu, F.-L., Huang, S.-H., Diao, M.-Q., Li, S.-X., Zhang, X.-J., Kosten, T. R., Shi, J., Bao, Y.-P., Lu, L., & Han, Y. (2024). Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis. Psychiatry Research, 335, 115886. https://doi.org/10.1016/j.psychres.2024.115886
Yerubandi, A., Thomas, J. E., Bhuiya, N. M. M. A., Harrington, C., Villa Zapata, L., & Caballero, J. (2024). Acute Adverse Effects of Therapeutic Doses of Psilocybin: A Systematic Review and Meta-Analysis. JAMA Network Open, 7(4). https://doi.org/10.1001/jamanetworkopen.2024.5960
Yu, C.-L., Liang, C.-S., Yang, F.-C., Tu, Y.-K., Hsu, C.-W., Carvalho, A. F., Stubbs, B., Thompson, T., Tsai, C.-K., Yeh, T.-C., Yang, S.-N., Shin, J. I., Chu, C.-S., Tseng, P.-T., & Su, K.-P. (2022). Trajectory of Antidepressant Effects after Single- or Two-Dose Administration of Psilocybin: A Systematic Review and Multivariate Meta-Analysis. Journal of Clinical Medicine, 11(4), 938. https://doi.org/10.3390/jcm11040938
Žuljević, M. F., Breški, N., Kaliterna, M., & Hren, D. (2024). Attitudes of European psychiatrists on psychedelics: a qualitative study. Frontiers in Psychiatry, 15. https://doi.org/10.3389/fpsyt.2024.1411234
Views:
49
Downloads:
16
Copyright (c) 2026 Łukasz Deska, Cezary Kosmecki, Dawid Głaz, Natalia Kamińska, Wojciech Sołtys, Magdalena Stolarczyk, Maksymilian Głaz, Mateusz Stronczyński, Aleksandra Jagura-Sukiennik, Julia Wawerska
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
